Blood-brain barrier (BBB) dysfunction is reemerging as a critical component of Alzheimer’s disease (AD). Higher BBB leakiness is one of the mechanistic pathways through which AD risk factors induce cognitive decline. We have previously demonstrated that epidermal growth factor (EGF) prevents BBB leakiness in a model of two important AD risk factors: APOE4 and female sex (female E4FAD mice). The goal of this study was to use Diffusion Weighted Arterial Spin Labeling MRI to determine whether post-symptomatic EGF treatment, (during 8-10 months) can reduce BBB leakiness in EGF treated mice compared to vehicle controls.
This abstract and the presentation materials are available to members only; a login is required.